Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience
Tayyaba Bhatti(University of Saskatchewan), Shahid Ahmed(Emory University), Osama Souied(University of Saskatchewan), Haji Chalchal, Mike Moser(Roswell Park Comprehensive Cancer Center), John M. Shaw(University of Saskatchewan), Kiat Tsong Tan(University of Saskatchewan), Adnan Zaidi(University of Saskatchewan), Dilip Gill(University of Saskatchewan), Duc Le(University of Saskatchewan)
Cited by 4
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301
A Randomized Clinical Trial of Granulocyte Transfusions for Infection in Acute Leukemia
|New England Journal of Medicine|1977|299
The Genotype-Tissue Expression (GTEx) project
|Nature Genetics|2013|266